Target intelligence / Profile preview

Hairy and enhancer of split 1 (HES1)

Target
HES1
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein, Notch signaling pathway effector
01

Overview

Hairy and enhancer of split 1 (HES1) is a basic helix-loop-helix (bHLH) transcriptional repressor encoded by the HES1 gene, originally identified as the mammalian homolog of the Drosophila hairy gene[1]. HES1 is a critical effector of the Notch signaling pathway, acting to suppress gene expression via binding to specialized DNA motifs (N-box) and regulating neural progenitor maintenance, timing of neurogenesis, and balancing differentiation in multiple tissues. It also regulates osteoblast and osteoclast function, influencing bone development and mass, and protects cells from endoplasmic reticulum stress-induced apoptosis by repressing pro-apoptotic genes such as GADD34[1][2][3][4]. Dysregulation of HES1 is implicated in various pathological processes, including cancer, developmental disorders, and bone diseases. No drugs directly target HES1 in clinical practice, but its central role in key gene regulatory networks makes it a subject of ongoing biomedical research.

Other names
HES1Hairy/enhancer-of-split related with YRPW motif 1bHLHb39hHES1
02

Mechanism of action

Drugs or modulators would act by interfering with DNA binding, dimerization, protein-protein interactions, or stability of HES1. No established direct therapeutic drugs targeting HES1 are clinically available[1][4].

03

Biological functions

Transcriptional repressionRegulation of cell differentiation (especially neural and osteoblast)Maintenance of stem cell stateCell fate determinationNegative regulation of neurogenesisModulation of apoptosis (in ER stress)
04

Disease associations

CancerNeurodevelopmental disordersOsteopenia/osteoporosisOther developmental disorders
05

Safety considerations

Manipulation may cause stem cell depletion, interfere with neurogenesis, or affect bone remodeling, potentially leading to neurological or skeletal side effects[2][4].
06

Interacting drugs

None established or clinically validated as of current knowledge
07

Biomarkers

HES1 expression is explored as a biomarker in some cancer contexts and in stem/progenitor cell maintenance, but none established clinically for approved patient selection[1][4].

Beyond the preview

Go deeper on Hairy and enhancer of split 1 (HES1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hairy and enhancer of split 1 (HES1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call